| Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC FW Peng, J Xuan, TT Wu, JY Xue, ZW Ren, DK Liu, XQ Wang, XH Chen, ... European journal of medicinal chemistry 109, 1-12, 2016 | 78 | 2016 |
| Discovery of imidazo [1, 2-a] pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 … L Zhang, NR Lakkaniga, JB Bharate, N Mcconnell, X Wang, A Kharbanda, ... European journal of medicinal chemistry 225, 113776, 2021 | 15 | 2021 |
| Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose HL Lingtian Zhang, Marialuisa Moccia, David C. Briggs, Jaideep B. Bharate ... Journal of Medicinal Chemistry 65, 1536−1551, 2022 | 11 | 2022 |
| An imidazo [1, 2-a] pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L X Wang, RA DeFilippis, TG Weldemichael, N Gunaganti, P Tran, ... European Journal of Medicinal Chemistry 264, 115977, 2024 | 5 | 2024 |
| Overcoming Secondary Mutations of Type II Kinase Inhibitors X Wang, RA DeFilippis, W Yan, NP Shah, H Li Journal of Medicinal Chemistry, 2024 | 3 | 2024 |
| N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl) imidazo [1, 2-a] pyridin-3-yl) pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits … X Wang, RA DeFilippis, YK Leung, NP Shah, H Li Bioorganic Chemistry 143, 106966, 2024 | 1 | 2024 |
| Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss X Wang, AY Sato, S Marino, N Akel, G Boysen, AG Basnakian, TM Bellido, ... Journal of Medicinal Chemistry 67 (22), 20708-20720, 2024 | | 2024 |
Yuet-Kin LeungUniversity of Arkansas for Medical Sciences在 uams.edu 的电子邮件经过验证
